Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Eyenovia to Present at Upcoming BTIG Ophthalmology Day | ||||||||
| By: GlobeNewswire - 23 Nov 2022 | Back to overview list |
|||||||
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022. Presentation details are below: BTIG Ophthalmology Day
The Eyenovia management team will be participating in one-on-one meetings at the event. Investors interested in meeting with Eyenovia at either conference should contact their BTIG representative. About Eyenovia, Inc. Eyenovia, Inc. (Nasdaq: EYEN) is a pre-commercial ophthalmic technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com. The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations. Eyenovia Contact: Eyenovia Investor Contact: Eyenovia Media Contact: 
|
||||||||
|
||||||||
 | Back to overview list | |||||||